STTKMEDIUM SIGNALFINANCIAL10-K

STTK shows significant operational improvement with 35% reduction in net losses and 34% improvement in operating cash flow, despite an 83% revenue decline and 49% increase in outstanding shares indicating dilutive financing.

The substantial reduction in R&D spending and operating losses suggests the company is managing its cash burn more effectively as it advances its clinical-stage DR3 blocking antibody program. However, the dramatic revenue drop and significant share dilution (from 48M to 72M shares) indicates the company likely raised capital through equity financing while scaling back operations.

Comparing 2026-03-05 vs 2025-03-27View on EDGAR →
FINANCIAL ANALYSIS

STTK's financials reflect a mixed picture of improved operational discipline amid funding pressures. While revenue collapsed 83% to just $1.0M, the company significantly reduced its cash burn with R&D expenses down 48% and operating cash flow improving 34% to -$39.9M, demonstrating tighter cost management. The 49% increase in outstanding shares to 72M combined with reduced liabilities suggests the company successfully raised equity capital while paying down obligations, providing runway to advance its clinical programs albeit with significant shareholder dilution.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-82.5%
$5.7M→$1.0M

Revenue declined 82.5% — significant demand weakness or market share loss warrants investigation.

R&D Expense
P&L
-47.5%
$67.2M→$35.3M

R&D spending cut 47.5% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+36.1%
-$80.6M→-$51.5M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+35.3%
-$75.4M→-$48.8M

Net income grew 35.3% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+34.1%
-$60.5M→-$39.9M

Operating cash flow surged 34.1% — exceptional cash generation, highest quality earnings signal.

Total Liabilities
Balance Sheet
-24.4%
$11.4M→$8.6M

Liabilities reduced 24.4% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-20.9%
$8.9M→$7.1M

Current liabilities reduced — improved short-term financial position and working capital health.

Capital Expenditure
Cash Flow
+20.3%
$59K→$71K

Capex increased 20.3% — ongoing investment in capacity or infrastructure for future growth.

LANGUAGE CHANGES
NEW — 2026-03-05
PRIOR — 2025-03-27
ADDED
As of February 26, 2026 the registrant had 71,564,217 shares of common stock, $0.0001 par value per share, outstanding.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 84 Item 9B.
Business Overview We are a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific Death Receptor 3 ( DR3 ) blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases.
Our expertise in protein engineering and the development of novel tumor necrosis factor ( TNF ) receptor therapeutics come together in our lead program, SL-325, a potentially first-in-class DR3 blocking antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway than TL1A blocking antibodies.
DR3 is the sole known receptor for tumor necrosis factor like ligand 1A ( TL1A ).
Additionally, we expect that SL-325 has the potential to demonstrate a superior immunogenicity profile in comparison to TL1A blocking antibodies.
By targeting DR3 instead of TL1A, we expect to avoid the formation of immune complexes, which we believe are the primary source of immunogenicity for all TL1A blocking antibodies, and lead to high rates of anti-drug antibody ( ADA ) formation toward TL1A targeting antibodies.
ADA to TL1A targeting antibodies has been shown to reduce efficacy in IBD patients.
We are currently conducting a single ascending dose ( SAD ) and multiple ascending dose ( MAD ) Phase 1 clinical trial evaluating SL-325 in healthy volunteers.
We expect this Phase 1 clinical trial to be completed in the second quarter of 2026.
REMOVED
As of March 17, 2025, the registrant had 47,899,240 shares of common stock, $0.0001 par value per share, outstanding.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 83 Item 9A.
Business Overview We are a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases.
We are developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease ("IBD") and other inflammatory and immune-mediated diseases.
Our expertise in protein engineering and the development of novel tumor necrosis factor ("TNF") receptor therapeutics come together in our lead program, SL-325, which we believe could be a first-in-class death receptor 3 ("DR3") antagonist antibody.
Because DR3 is expressed on circulating, peripheral blood lymphocytes, we are able to directly measure DR3 receptor occupancy ( RO ), and our preclinical studies suggest that blockade may last for at least one month as a result of the properties of SL-325 and the stable expression of DR3.
The RO and pharmacokinetic ( PK ) profile of SL-325 suggests extended dosing intervals, which we intend to further characterize in our upcoming Phase 1 clinical trial.
Finally, the human protein decoy receptor 3 ( DcR3 ) neutralizes soluble TL1A, Fas Ligand and LIGHT, which all induce a proinflammatory immune response.
DcR3 serves as a sink for these proteins, tempering the proinflammatory immune signaling.
We are planning initial clinical development of SL-325 in patients with IBD, including UC and CD.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →